Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06512493
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-16
Brief Title:
South East Zuid Oost Netherlands Heart Registry
Sponsor:
None
Organization:
None
Study Overview
Official Title:
South East Zuid Oost Netherlands Heart Registry ZON-HR
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ZON-HR
Brief Summary:
Rationale Patients undergoing percutaneous coronary intervention PCI for chronic coronary syndrome CCS or acute coronary syndrome ACS have a residual risk of ischemic events after PCI due to the progression of atherosclerosis in and outside the stented segments The residual risk is affected by thrombotic lipid inflammation and diabetic risk factors Secondary prevention after PCI is therefore of major importance to reduce complications and improve the patients prognosis
Objective To provide an extensive overview on the quality of secondary prevention and personalized medicine a consortium in the South East Netherlands has created a PCI registry the Zuid Oost Nederland Hart Registratie ZON-HR
Objective To provide an extensive overview on the quality of secondary prevention and personalized medicine a consortium in the South East Netherlands has created a PCI registry the Zuid Oost Nederland Hart Registratie ZON-HR
Detailed Description:
Rationale Patients undergoing percutaneous coronary intervention PCI for chronic coronary syndrome CCS or acute coronary syndrome ACS have a residual risk of ischemic events after PCI due to the progression of atherosclerosis in and outside the stented segments The residual risk is affected by thrombotic lipid inflammation and diabetic risk factors Secondary prevention after PCI is therefore of major importance to reduce complications and improve the patients prognosis Antithrombotic treatment plays a major role in the reduction of thromboembolic events and is therefore key in secondary prevention However this treatment increases the risk of bleeding complications Therefore a personalized antiplatelet strategy is recommended by the guidelines Together with the antithrombotic treatment lipid management is the cornerstone of secondary prevention As low density lipoproteins cholesterol LDL-C increases the risk for atherosclerotic cardiovascular disease the current ESC guidelines recommend a LDL-C value 14mmolL in patients undergoing PCI Personalized medicine in which the treatment and lifestyle advice after PCI is adjusted on the patients risk factors such as high bleeding- or thromboembolic risk high LDL cholesterol levels hypertension or the presence of diabetes mellitus DM is of major importance to lower the residual risk of complications and revascularisation However due to the large amount of risk factors that should be considered personalized medicine is challenging which can lead to under treatment
Objective To maintain and improve quality of care throughout the Netherlands all interventional centres deliver data regarding patient- and procedural characteristics and follow-up after PCI to the Netherland Heart Registry NHR The NHR processes the data and provides these centres with feedback 16 However the registration of baseline- procedural- and follow-up parameters by the NHR is concise and mainly focuses on mortality and ischemia driven revascularisation To enhance the potency of this PCI registry a consortium in the South East region of the Netherlands has created an extended version The Zuid Oost Nederland Hart Registratie ZON-HR With this comprehensive registry the ZON-HR provides a more extensive overview on the quality of secondary prevention and personalized medicine Furthermore the ZON-HR consortium aims to improve secondary prevention post-PCI by stimulating a personalized approach Also it will provide a platform for research regarding secondary prevention
Objective To maintain and improve quality of care throughout the Netherlands all interventional centres deliver data regarding patient- and procedural characteristics and follow-up after PCI to the Netherland Heart Registry NHR The NHR processes the data and provides these centres with feedback 16 However the registration of baseline- procedural- and follow-up parameters by the NHR is concise and mainly focuses on mortality and ischemia driven revascularisation To enhance the potency of this PCI registry a consortium in the South East region of the Netherlands has created an extended version The Zuid Oost Nederland Hart Registratie ZON-HR With this comprehensive registry the ZON-HR provides a more extensive overview on the quality of secondary prevention and personalized medicine Furthermore the ZON-HR consortium aims to improve secondary prevention post-PCI by stimulating a personalized approach Also it will provide a platform for research regarding secondary prevention
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None